UCP2 Upregulation Increases Fra-1 Expression and S-phase Cell Population without Decreasing Apoptosis during Skin Cell Transformation
Main Article Content
Abstract
Upregulation of uncoupling protein 2 (UCP2) is considered a prosurvival mechanism for cancer cells. This prosurvival function is thought to be mediated by UCP2’s uncoupling activity which reduces the production of superoxide in the mitochondria. However, exactly how highly expressed UCP2 regulates cell proliferation, cell cycle, and cell death during the early stage of tumorigenesis has not been studied thoroughly. For this purpose, we generated UCP2 stably overexpressed JB6 Cl-41 cells (a skin cell transformation model) and performed studies to answer the above questions. Our results demonstrated that UCP2 overexpression enhanced cell proliferation, activation of the oncoprotein Fra-1, anchorage-independent growth, 3D spheroids growth, and glucose uptake during skin cell transformation. Next, our results demonstrated that UCP2 overexpression resulted in marked decreases in the proportion of the cells in the G1 phase and an increase of cells in the S phase of the cell cycle, which was accompanied by increased expression of Cyclin E and Cdk2. Lastly, UCP2 overexpression did not enhance or suppress apoptosis during skin cell transformation, as indicated by Annexin V and active caspase 3/7 staining. Taken together, these data suggest that UCP2 upregulation mainly enhances the Fra-1 oncogenic pathway which drives cell proliferation, without inhibiting apoptosis during skin cell transformation.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2) Fleury C, Neverova M, Collins S, et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet. 1997;15:269-272.
3) Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005;2:85-93.
4) Sreedhar A, Zhao Y. Uncoupling protein 2 and metabolic diseases. Mitochondrion. 2017; 34:135-140.
5) Horimoto M, Resnick MB, Konkin TA, et al. Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res. 2004;10:6203-6207.
6) Derdak Z, Mark NM, Beldi G, et al. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 2008;68:2813-2819.
7) Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579-591.
8) Li W, Nichols K, Nathan CA, et al. Mitochondrial uncoupling protein 2 is up-regulated in human head and neck, skin, pancreatic, and prostate tumors. Cancer Biomark. 2013;13:377-383.
9) Valle A, Oliver J, Roca P. Role of uncoupling proteins in cancer. Cancers. 2010;2:567-591.
10) Colburn NH, Bruegge WV, Bates JR, et al. Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res. 1978;38:624-634.
11) Sadikovic B, Al-Romaih K, Squire JA, et al. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics. 2008;9:394-408.
12) Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. Front Oncol. 2013;3:292.
13) Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004;287:C817-833.
14) Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;1:9.
15) Modica-Napolitano JS, Singh KK. Mitochondrial dysfunction in cancer. Mitochondrion. 2004;4:755-762.
16) Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407.
17) King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem. 1995;58:175-180.
18) Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342-348.
19) Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10:13-29.
20) Li W, Zhang C, Jackson K, et al. UCP2 knockout suppresses mouse skin carcinogenesis. Cancer Prev Res. 2015;8:487-491.
21) Sreedhar A, Lefort J, Petruska P, et al. UCP2 upregulation promotes PLCγ‐1 signaling during skin cell transformation. Mol Carcinog. 2017;56:2290-2300.
22) Sreedhar A, Petruska P, Miriyala S, et al. UCP2 overexpression enhanced glycolysis via activation of PFKFB2 during skin cell transformation. Oncotarget. 2017;8:95504-95515.
23) Bernstein LR, Colbrun NH. AP1-jun function is differently induced in promotion-sensitive and resistant JB6 cells. Science. 1989;244:566-570.
24) Dong Z, Birrer MJ, Watts RG, et al. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA. 1994;91:609-613.
25) Fujikawa S, Nakamura S, Koga K. Genipin, a new type of protein crosslinking reagent from gardenia fruits. Agricultural and biological chemistry. 1988;52:869-870.
26) Qiu W, Zhou Y, Jiang L, et al. Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice. PLoS One. 2012;7:e41391.
27) Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
28) Luby A, Alves-Guerra MC. UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control. Int J Mol Sci. 2022 Dec 1;23(23):15077.
29) Ge H, Zhang F, Shan D, et al. Effects of mitochondrial uncoupling protein 2 inhibition by genipin in human cumulus cells. Biomed Res Int. 2015;2015:323246.
30) Deng S, Yang Y, Han Y, et al. UCP2 inhibits ROS-mediated apoptosis in A549 under hypoxic conditions. PLoS One. 2012;7:e30714.